NCT Number: NCT00395577
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Call For Information, Dimitrovgrad, Bulgaria
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adult patients 18 to 75 years of age with active RA
- Must have been taking MTX for at least 6 months
- No concurrent DMARD treatment (other than a stable dose of MTX)
Exclusion criteria
- Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study
- Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1
Treatment and study plan
Primary outcomes
-
To evaluate the effects of VX-702 administered with concomitant methotrexate (MTX), and MTX alone
Secondary outcomes
-
To evaluate the safety and tolerability of VX-702 administered with concomitant MTX, and MTX alone
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Registry information
Official study title
A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Nov 3, 2006
- Registry last updated
- Dec 7, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis
NCT06565273
Arthritis, Arthritis, Rheumatoid
Aveiro, Portugal
View Trial DetailsA Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
NCT06020144
Arthritis, Arthritis, Rheumatoid
Beijing, Beijing Municipality, China
View Trial DetailsHealth Literacy, Rational Drug Use, and Cyberchondria in Rheumatic Diseases
NCT06993935
Arthritis, Arthritis, Rheumatoid
Yozgat, Turkey (Türkiye)
View Trial DetailsUmbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis
NCT07715045
Arthritis, Arthritis, Rheumatoid
Palembang, South Sumatera, Indonesia
View Trial Details